The Global Hepatitis B Vaccine Market Size accounted for USD 6.13 Billion in 2024 and is estimated to achieve a market size of USD 10.08 Billion by 2033 growing at a CAGR of 5.8% from 2025 to 2033.
The global Hepatitis B vaccine market plays a pivotal role in controlling and preventing Hepatitis B virus (HBV) infections, which continue to pose significant public health challenges worldwide. Hepatitis B is a viral infection that affects the liver, leading to conditions such as cirrhosis, liver cancer, and acute liver failure, making vaccination a critical tool for public health systems globally. The introduction of the Hepatitis B vaccine has contributed to a considerable reduction in the global prevalence of HBV infections, especially in regions with high endemicity. As the demand for effective vaccination increases due to rising awareness and a focus on prevention, the Hepatitis B vaccine market is expanding, driven by factors such as increasing vaccination coverage, government initiatives, and advancements in vaccine development technologies.
Hepatitis B Vaccine Market Segmentation
The worldwide market for hepatitis B vaccine is split based on technology, doses, age, end-user, and geography.
Hepatitis B Vaccine Market By Type
Single Antigen Hepatitis B Vaccine
Combination Vaccines
Hepatitis B Vaccine Market By Doses
3-Dose Schedule
2-Dose Schedule
Alternate Schedule
Hepatitis B Vaccine Age
Pediatrics
Adults
Hepatitis B Vaccine End-user
Hospitals
Clinics
Others
Hepatitis B Vaccine Market Regional Outlook
North America
U.S.
Canada
Europe
U.K.
Germany
France
Spain
Rest of Europe
Asia-Pacific
India
Japan
China
Australia
South Korea
Rest of Asia-Pacific
Latin America
Brazil
Mexico
Rest of LATAM
The Middle East & Africa
South Africa
GCC Countries
Rest of the Middle East & Africa (ME&A)
Hepatitis B Vaccine Market Players
Some of the top hepatitis B vaccine companies offered in our report includes Dynavax Technologies, Novartis AG, Emergent Biosolutions, Beijing Minhai Biotechnology, GlaxoSmithKline Biologicals, Merck & Co, Inc, CSL Ltd, Sinovac Biotech, Pfizer Inc., Sanofi Pasteur, Serum Institute of India, and Emergent Biosolutions.
How Acumen Research and Consulting Reserch Study of helps clients in their decision making:
Creating strategies for new product development
Supporting & Adjust Investment/business decisions
Benchmark and judge own competitiveness
Aiding in the business planning process
Serving as a credible, independent check on company internal forecasts
Supporting acquisition strategies
- CHAPTER 1 Industry Overview of Hepatitis B Vaccine Market
- 1.1 Definition and Scope
- 1.2 Summary
- CHAPTER 2 Research Approach
- 2.1 Methodology
- 2.2 Data Source
- CHAPTER 3 Market Dynamics And Competition Analysis
- 3.1 Market Drivers
- 3.2 Restraints and Challenges
- 3.3 Growth Opportunities
- 3.4 Porter’s Five Forces Analysis
- 3.4.1 Bargaining Power of Suppliers
- 3.4.2 Bargaining Power of Buyers
- 3.4.3 Threat of Substitute
- 3.4.4 Threat of New Entrants
- 3.4.5 Degree of Competition
- 3.5 Market Concentration Ratio and Market Maturity Analysis of Hepatitis B Vaccine Market
- 3.5.1 Go To Market Strategy
- 3.5.1.1 Introduction
- 3.5.1.2 Growth
- 3.5.1.3 Maturity
- 3.5.1.4 Saturation
- 3.5.1.5 Possible Development
- 3.6 Technological Roadmap for Hepatitis B Vaccine Market
- 3.7 Value Chain Analysis
- 3.7.1 List of Key Manufacturers
- 3.7.2 List of Customers
- 3.7.3 Level of Integration
- 3.8 Cost Structure Analysis
- 3.8.1 Price Trend of Key Raw Materials
- 3.8.2 Raw Material Suppliers
- 3.8.3 Proportion of Manufacturing Cost Structure
- 3.8.3.1 Raw Material
- 3.8.3.2 Labor Cost
- 3.8.3.3 Manufacturing Expense
- 3.9 Regulatory Compliance
- 3.10 Competitive Landscape, 2024
- 3.10.1 Player Positioning Analysis
- 3.10.2 Key Strategies Adopted By Leading Players
- CHAPTER 4 Manufacturing Plant Analysis
- 4.1 Manufacturing Plant Location and Establish Date of Major Manufacturers in 2024
- 4.2 R&D Status of Major Manufacturers in 2024
- CHAPTER 5 Hepatitis B Vaccine Market By Type
- 5.1 Introduction
- 5.2 Hepatitis B Vaccine Revenue By Type
- 5.2.1 Hepatitis B Vaccine Revenue (USD Billion) and Forecast, By Type, 2021-2033
- 5.2.2 Single Antigen Hepatitis B Vaccine
- 5.2.2.1 Single Antigen Hepatitis B Vaccine Market Revenue (USD Billion) and Growth Rate (%), 2021-2033
- 5.2.3 Combination Vaccines
- 5.2.3.1 Combination Vaccines Market Revenue (USD Billion) and Growth Rate (%), 2021-2033
- CHAPTER 6 Hepatitis B Vaccine Market By Doses
- 6.1 Introduction
- 6.2 Hepatitis B Vaccine Revenue By Doses
- 6.2.1 Hepatitis B Vaccine Revenue (USD Billion) and Forecast, By Doses, 2021-2033
- 6.2.2.3 Dose Schedule
- 6.2.2.1.3 Dose Schedule Market Revenue (USD Billion) and Growth Rate (%), 2021-2033
- 6.2.3.2 Dose Schedule
- 6.2.3.1.2 Dose Schedule Market Revenue (USD Billion) and Growth Rate (%), 2021-2033
- 6.2.4 Alternate Schedule
- 6.2.4.1 Alternate Schedule Market Revenue (USD Billion) and Growth Rate (%), 2021-2033
- CHAPTER 7 Hepatitis B Vaccine Market By Age
- 7.1 Introduction
- 7.2 Hepatitis B Vaccine Revenue By Age
- 7.2.1 Hepatitis B Vaccine Revenue (USD Billion) and Forecast, By Age, 2021-2033
- 7.2.2 Pediatrics
- 7.2.2.1 Pediatrics Market Revenue (USD Billion) and Growth Rate (%), 2021-2033
- 7.2.3 Adults
- 7.2.3.1 Adults Market Revenue (USD Billion) and Growth Rate (%), 2021-2033
- CHAPTER 8 Hepatitis B Vaccine Market By End-user
- 8.1 Introduction
- 8.2 Hepatitis B Vaccine Revenue By End-user
- 8.2.1 Hepatitis B Vaccine Revenue (USD Billion) and Forecast, By End-user, 2021-2033
- 8.2.2 Hospitals
- 8.2.2.1 Hospitals Market Revenue (USD Billion) and Growth Rate (%), 2021-2033
- 8.2.3 Clinics
- 8.2.3.1 Clinics Market Revenue (USD Billion) and Growth Rate (%), 2021-2033
- 8.2.4 Others
- 8.2.4.1 Others Market Revenue (USD Billion) and Growth Rate (%), 2021-2033
- CHAPTER 9 North America Hepatitis B Vaccine Market By Country
- 9.1 North America Hepatitis B Vaccine Market Overview
- 9.2 U.S.
- 9.2.1 U.S. Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2021-2033
- 9.2.2 U.S. Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Doses, 2021-2033
- 9.2.3 U.S. Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Age, 2021-2033
- 9.2.4 U.S. Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End-Use, 2021-2033
- 9.3 Canada
- 9.3.1 Canada Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2021-2033
- 9.3.2 Canada Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Doses, 2021-2033
- 9.3.3 Canada Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Age, 2021-2033
- 9.3.4 Canada Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End Use, 2021-2033
- 9.4 North America PEST Analysis
- CHAPTER 10 Europe Hepatitis B Vaccine Market By Country
- 10.1 Europe Hepatitis B Vaccine Market Overview
- 10.2 U.K.
- 10.2.1 U.K. Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2021-2033
- 10.2.2 U.K. Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Doses, 2021-2033
- 10.2.3 U.K. Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Age, 2021-2033
- 10.2.4 U.K. Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End Use, 2021-2033
- 10.3 Germany
- 10.3.1 Germany Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2021-2033
- 10.3.2 Germany Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Doses, 2021-2033
- 10.3.3 Germany Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Age, 2021-2033
- 10.3.4 Germany Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End Use, 2021-2033
- 10.4 France
- 10.4.1 France Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2021-2033
- 10.4.2 France Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Doses, 2021-2033
- 10.4.3 France Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Age, 2021-2033
- 10.4.4 France Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End Use, 2021-2033
- 10.5 Spain
- 10.5.1 Spain Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2021-2033
- 10.5.2 Spain Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Doses, 2021-2033
- 10.5.3 Spain Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Age, 2021-2033
- 10.5.4 Spain Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End Use, 2021-2033
- 10.6 Rest of Europe
- 10.6.1 Rest of Europe Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2021-2033
- 10.6.2 Rest of Europe Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Doses, 2021-2033
- 10.6.3 Rest of Europe Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Age, 2021-2033
- 10.6.4 Rest of Europe Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End Use, 2021-2033
- 10.7 Europe PEST Analysis
- CHAPTER 11 Asia Pacific Hepatitis B Vaccine Market By Country
- 1.1 Asia Pacific Hepatitis B Vaccine Market Overview
- 11.2 China
- 11.2.1 China Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2021-2033
- 11.2.2 China Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Doses, 2021-2033
- 11.2.3 China Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Age, 2021-2033
- 11.2.4 China Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End Use, 2021-2033
- 11.3 Japan
- 11.3.1 Japan Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2021-2033
- 11.3.2 Japan Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Doses, 2021-2033
- 11.3.3 Japan Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Age, 2021-2033
- 11.3.4 Japan Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End Use, 2021-2033
- 11.4 India
- 11.4.1 India Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2021-2033
- 11.4.2 India Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Doses, 2021-2033
- 11.4.3 India Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Age, 2021-2033
- 11.4.4 India Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End Use, 2021-2033
- 11.5 Australia
- 11.5.1 Australia Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2021-2033
- 11.5.2 Australia Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Doses, 2021-2033
- 11.5.3 Australia Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Age, 2021-2033
- 11.5.4 Australia Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End Use, 2021-2033
- 11.6 South Korea
- 11.6.1 South Korea Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2021-2033
- 11.6.2 South Korea Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Doses, 2021-2033
- 11.6.3 South Korea Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Age, 2021-2033
- 11.6.4 South Korea Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End Use, 2021-2033
- 11.7 Rest of Asia-Pacific
- 11.7.1 Rest of Asia-Pacific Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2021-2033
- 11.7.2 Rest of Asia-Pacific Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Doses, 2021-2033
- 11.7.3 Rest of Asia-Pacific Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Age, 2021-2033
- 11.7.4 Rest of Asia-Pacific Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End Use, 2021-2033
- 11.8 Asia Pacific PEST Analysis
- CHAPTER 12 Latin America Hepatitis B Vaccine Market By Country
- 12.1 Latin America Hepatitis B Vaccine Market Overview
- 12.2 Brazil
- 12.2.1 Brazil Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2021-2033
- 12.2.2 Brazil Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Doses, 2021-2033
- 12.2.3 Brazil Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Age, 2021-2033
- 12.2.4 Brazil Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End Use, 2021-2033
- 12.3 Mexico
- 12.3.1 Mexico Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2021-2033
- 12.3.2 Mexico Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Doses, 2021-2033
- 12.3.3 Mexico Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Age, 2021-2033
- 12.3.4 Mexico Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End Use, 2021-2033
- 12.4 Rest of Latin America
- 12.4.1 Rest of Latin America Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2021-2033
- 12.4.2 Rest of Latin America Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Doses, 2021-2033
- 12.4.3 Rest of Latin America Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Age, 2021-2033
- 12.4.4 Rest of Latin America Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End Use, 2021-2033
- 12.5 Latin America PEST Analysis
- CHAPTER 13 Middle East & Africa Hepatitis B Vaccine Market By Country
- 13.1 Middle East & Africa Hepatitis B Vaccine Market Overview
- 13.2 GCC
- 13.2.1 GCC Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2021-2033
- 13.2.2 GCC Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Doses, 2021-2033
- 13.2.3 Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Age, 2021-2033
- 13.2.4 Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End Use, 2021-2033
- 13.3 South Africa
- 13.3.1 South Africa Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2021-2033
- 13.3.2 South Africa Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Doses, 2021-2033
- 13.3.3 South Africa Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Age, 2021-2033
- 13.3.4 South Africa Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End Use, 2021-2033
- 13.4 Rest of Middle East & Africa
- 13.4.1 Rest of Middle East & Africa Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Type, 2021-2033
- 13.4.2 Rest of Middle East & Africa Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Doses, 2021-2033
- 13.4.3. Rest of Middle East & Africa Hepatitis B Vaccine Revenue (USD Billion) and Forecast By Age, 2021-2033
- 13.4.4 Rest of Middle East & Africa Hepatitis B Vaccine Revenue (USD Billion) and Forecast By End Use, 2021-2033
- 13.5 Middle East & Africa PEST Analysis
- CHAPTER 14 Player Analysis Of Hepatitis B Vaccine Market
- 14.1 Hepatitis B Vaccine Market Company Share Analysis
- 14.2 Competition Matrix
- 14.2.1 Competitive Benchmarking of key players by price, presence, market share, and R&D investment
- 14.2.2 New Product Launches and Product Enhancements
- 14.2.3 Mergers And Acquisition In Global Hepatitis B Vaccine Market
- 14.2.4 Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
- CHAPTER 15 Company Profile
- 15.1 Dynavax Technologies
- 15.1.1 Company Snapshot
- 15.1.2 Business Overview
- 15.1.3 Financial Overview
- 15.1.3.1 Revenue (USD Billion), 2024
- 15.1.3.2 Dynavax Technologies 2024 Hepatitis B Vaccine Business Regional Distribution
- 15.1.4 Product /Service and Specification
- 15.1.5 Recent Developments & Business Strategy
- 15.2 Novartis AG
- 15.3 Emergent Biosolutions
- 15.4 Beijing Minhai Biotechnology
- 15.5 GlaxoSmithKline Biologicals
- 15.6 Merck & Co, Inc
- 15.7 CSL Ltd.
- 15.8 Sinovac Biotech
- 15.9 Pfizer Inc.
- 15.10 Sanofi Pasteur
- 15.11 Serum Institute of India
- 15.12 Emergent Biosolutions
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook